Document is current
Any future updates will be listed below
-
Authors
Yang, Jianliang
Song, Yongping
Zhou, Keshu
Li, Zhiming
Zhang, Mingzhi
Jing, Hongmei
Wang, Zhen
Yu, Li
Meng, Wei
Lu, Qiying
Tian, Wenzhi
Shi, Yuankai https://orcid.org/0000-0002-3342-4964
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05805943 at ClinicalTrials.govDocuments that mention this clinical trial
Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.7060
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPĪ±, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study
https://doi.org/10.1186/s13045-024-01646-2
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 28 November 2024
First Online: 18 December 2024
Declarations
:
: W.M. and Q.L. are employees in Biopharmaceuticals (Shanghai) Inc., Shanghai, China. W.T. is the founder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China. All other authors declare no competing interests.
